Ann: Half Year Results Analyst Presentation, page-188

ive held csl since buying between 80-105 dollars over the last year or two and i love the company long term but the valuation does appear to be getting pretty frothy and im mostly worried about the effect of the huge cost of the csl-112 trial on earnings growth over the next couple of years.

wont a multivillion dollar trial weigh heavily on eps growth and keep it to single digits thus forcing a temporary downgrade by the market?

i know csl is a fantastic company but with such a huge market cap and eps, its not easy to grow eps at double digits of 15-20% especially as the cost of capital goes up with rising bond yields. this is somewhat offset by the weaker aud-usd rate which is a tailwind i guess.

anyway can some one please give me a detailed analysis of how csl-112 expense will weigh on eps growth over next 3-5 years?

im trying to convince myself not to sell...